Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Comp Med ; 70(2): 152-159, 2020 04 01.
Article in English | MEDLINE | ID: mdl-32183928

ABSTRACT

Chagas disease is a zoonotic vector-borne disease caused by infection with the protozoan parasite Trypanosoma cruzi. T. cruzi is found in Latin America and the Southern United States, where it infects many species, including humans and nonhuman primates (NHPs). NHPs are susceptible to natural infection and can develop clinical symptoms consistent with human disease, including Chagasic cardiomyopathy, gastrointestinal disease and transplacental transmission, leading to congenital infection. Due to evidence of Chagas transmission in Texas, this study hypothesized T. cruzi infection was present in a closed, outdoor-housed breeding colony of rhesus macaques (Macaca mulatta) located at a biomedical research facility in Central Texas. In addition, we questioned whether seropositive female rhesus macaques might experience reproductive complications consistent with maternal-fetal Chagas disease. The seroprevalence of T. cruzi infection in the colony was assessed using an Enzyme Linked Immunosorbant Assay (ELISA) to detect antibodies against Tc24 antigen as a screening assay, and a commercially available immunochromatographic test (Chagas Stat Pak) as a confirmatory assay. Retrospective serologic analysis was performed to confirm the status of all T. cruzi-infected animals between the years 2012 to 2016. The medical history of all seropositive and seronegative breeding females within the colony from 2012 to 2016 was reviewed to determine each animals' level of reproductive fitness. The percentage of T. cruzi-seropositive animals ranged from 6.7% to 9.7% in adult animals and 0% to 0.44% in juveniles or weanling animals, depending on the year. An overall 3.9% seroprevalence of T. cruzi infection was found in the total population. No significant differences in any measure of reproductive outcomes were identified between seropositive and seronegative females from 2012 to 2016. The lack of significant adverse reproductive outcomes reported here may help inform future management decisions regarding seropositive female rhesus macaques within breeding colonies.


Subject(s)
Chagas Disease/veterinary , Monkey Diseases , Pregnancy Outcome/veterinary , Animals , Enzyme-Linked Immunosorbent Assay/veterinary , Female , Macaca mulatta , Male , Pregnancy , Retrospective Studies , Seroepidemiologic Studies , Trypanosoma cruzi/isolation & purification
2.
Proc Natl Acad Sci U S A ; 115(11): 2806-2811, 2018 03 13.
Article in English | MEDLINE | ID: mdl-29490919

ABSTRACT

Over the past two decades, 33 cases of colonic adenocarcinomas have been diagnosed in rhesus macaques (Macaca mulatta) at the nonhuman primate colony of the Keeling Center for Comparative Medicine and Research at The University of Texas MD Anderson Cancer Center. The distinctive feature in these cases, based on PET/computed tomography (CT) imaging, was the presence of two or three tumor lesions in different locations, including proximal to the ileocecal juncture, proximal to the hepatic flexure, and/or in the sigmoid colon. These colon carcinoma lesions selectively accumulated [18F]fluorodeoxyglucose ([18F]FDG) and [18F]fluoroacetate ([18F]FACE) at high levels, reflecting elevated carbohydrate and fatty acid metabolism in these tumors. In contrast, the accumulation of [18F]fluorothymidine ([18F]FLT) was less significant, reflecting slow proliferative activity in these tumors. The diagnoses of colon carcinomas were confirmed by endoscopy. The expression of MLH1, MSH2, and MSH6 proteins and the degree of microsatellite instability (MSI) was assessed in colon carcinomas. The loss of MLH1 protein expression was observed in all tumors and was associated with a deletion mutation in the MLH1 promoter region and/or multiple single-nucleotide polymorphism (SNP) mutations in the MLH1 gene. All tumors exhibited various degrees of MSI. The pedigree analysis of this rhesus macaque population revealed several clusters of affected animals related to each other over several generations, suggesting an autosomal dominant transmission of susceptibility for colon cancer. The newly discovered hereditary nonpolyposis colorectal cancer syndrome in rhesus macaques, termed MLH1-rheMac, may serve as a model for development of novel approaches to diagnosis and therapy of Lynch syndrome in humans.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/veterinary , Macaca mulatta , MutL Protein Homolog 1/metabolism , Primate Diseases/metabolism , Animals , Colorectal Neoplasms, Hereditary Nonpolyposis/diagnostic imaging , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis/metabolism , Female , Macaca mulatta/genetics , Macaca mulatta/metabolism , Male , Microsatellite Instability , MutL Protein Homolog 1/genetics , Polymorphism, Single Nucleotide , Positron Emission Tomography Computed Tomography , Primate Diseases/diagnostic imaging , Primate Diseases/genetics , Primate Diseases/pathology
3.
Comp Med ; 62(3): 229-33, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22776057

ABSTRACT

A 10-y-old multiparous rhesus macaque presented for an annual routine physical examination. Clinically, the animal had pale mucous membranes, petechial and ecchymotic hemorrhages in multiple sites, and a laceration at the tail base. Severe pancytopenia was noted on hematologic evaluation. The monkey was seronegative for SIV, simian T-lymphotropic virus, simian retrovirus type D, and Macacine herpesvirus 1. Bone marrow evaluation revealed a paucity of megakaryocytic precursors in a hypercellular marrow with marked erythroid hyperplasia. In light of these findings, the diagnosis was acquired amegakaryocytic thrombocytopenia purpura. Due to the poor prognosis of the syndrome and clinical deterioration of the monkey, euthanasia was elected. A definitive cause of the thrombocytopenia was not identified; however, the syndrome may have developed secondary to a recent spontaneous abortion. To our knowledge, this case represents the first reported observation of acquired amegakaryocytic thrombocytopenia purpura in a rhesus monkey.


Subject(s)
Bone Marrow Diseases/diagnosis , Purpura, Thrombocytopenic/diagnosis , Animals , Macaca mulatta
4.
Am J Primatol ; 74(6): 518-27, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21905063

ABSTRACT

In captive research environments for nonhuman primates (NHP), social housing strategies are often in conflict with protocols designed to minimize disease transmission. This is particularly true in breeding colonies, and is especially relevant when attempting to eliminate specific pathogens from a population of primates. Numerous strategies have been used to establish such specific pathogen free (SPF) breeding colonies (primarily of macaques), ranging from nursery rearing of neonates to single housing of socially reared yearlings to the rearing of infants in large social groups. All these strategies attempt to balance the effects of the chosen socialization strategy on parameters related to disease transmission, including the ultimate elimination of the target pathogens. Such strategies may affect the overall disease states of NHP breeding colonies through selective breeding processes. This can occur either by creating subpopulations of animals that do not have target diseases (SPF colonies), but may have other issues; or by creating situations in which the "best" animals are sold and the breeding colony is stocked with animals that may be more disease susceptible than those that were sold. The disease states of NHP research colonies also may be affected by selective utilization programs, in which animals removed from the breeding colony for health/behavior reasons, are preferentially chosen for use in scientific investigations. Such utilization criteria raise the question of whether ideal subjects are being chosen for use in research. Finally, captive primate colonies, where both socialization and disease states are intensely managed, may provide opportunities for those testing predictions from models of the interactions of socialization and disease transmission in the evolution of wild populations of NHP. This would be especially true for some extreme conditions of these disease ecology models, given the exceedingly high social densities and levels of pathogen control that exist in many captive nonhuman primate colonies.


Subject(s)
Animals, Laboratory/virology , Primate Diseases/transmission , Social Behavior , Virus Diseases/veterinary , Animals , Animals, Laboratory/psychology , Female , Housing, Animal , Male , Primate Diseases/prevention & control , Primates , Virus Diseases/prevention & control , Virus Diseases/transmission
5.
Sci Transl Med ; 3(108): 108ra112, 2011 Nov 09.
Article in English | MEDLINE | ID: mdl-22072637

ABSTRACT

Obesity, defined as body mass index greater than 30, is a leading cause of morbidity and mortality and a financial burden worldwide. Despite significant efforts in the past decade, very few drugs have been successfully developed for the treatment of obese patients. Biological differences between rodents and primates are a major hurdle for translation of anti-obesity strategies either discovered or developed in rodents into effective human therapeutics. Here, we evaluate the ligand-directed peptidomimetic CKGGRAKDC-GG-(D)(KLAKLAK)(2) (henceforth termed adipotide) in obese Old World monkeys. Treatment with adipotide induced targeted apoptosis within blood vessels of white adipose tissue and resulted in rapid weight loss and improved insulin resistance in obese monkeys. Magnetic resonance imaging and dual-energy x-ray absorptiometry confirmed a marked reduction in white adipose tissue. At experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function. Together, these data in primates establish adipotide as a prototype in a new class of candidate drugs that may be useful for treating obesity in humans.


Subject(s)
Adipose Tissue, White/drug effects , Adipose Tissue, White/pathology , Insulin Resistance , Obesity/drug therapy , Peptidomimetics/pharmacology , Peptidomimetics/therapeutic use , Weight Loss/drug effects , Absorptiometry, Photon , Adipose Tissue, White/diagnostic imaging , Amino Acid Sequence , Animals , Anthropometry , Cercopithecidae , Disease Models, Animal , Dose-Response Relationship, Drug , Feeding Behavior , Female , Humans , Kidney/pathology , Kidney/physiopathology , Kidney Function Tests , Magnetic Resonance Imaging , Male , Molecular Sequence Data , Obesity/diagnostic imaging , Obesity/pathology , Obesity/physiopathology , Peptidomimetics/chemistry
6.
Clin Cancer Res ; 11(16): 5981-3, 2005 Aug 15.
Article in English | MEDLINE | ID: mdl-16115942

ABSTRACT

INTRODUCTION: Clofarabine (2-chloro-2'fluoro-2'-deoxy-9-beta-d-arabinofuranosyladenine) is a purine nucleoside analogue that is active in the treatment of acute leukemia. We studied the pharmacokinetics and cerebrospinal fluid penetration of clofarabine in a nonhuman primate model. METHODS: A dose of 2.3 mg/kg of clofarabine was given i.v. over 2 hours to each of four animals. Plasma and cerebrospinal fluid (CSF) samples were obtained at specified intervals and the clofarabine concentration determined by reverse-phase high-pressure liquid chromatography with mass spectroscopy. RESULTS: The median clofarabine clearance was 17 mL/min/kg (range, 15-20), the median plasma area under the concentration-time curve was 452 mumol/L minutes (range, 380-487), and the median terminal half-life was 105 minutes (range, 78-138). Concentrations of clofarabine in CSF could not be modeled reliably because the terminal rate constant was not well defined. The median CSF penetration was 5% (range, 3-26%). CONCLUSION: Clofarabine penetrates into the CSF only modestly, but the concentrations obtained may approach those that are cytotoxic in vitro. Evaluation of the contribution of clofarabine to central nervous system preventive therapy should be considered in future studies.


Subject(s)
Arabinonucleosides/pharmacokinetics , Adenine Nucleotides , Animals , Arabinonucleosides/blood , Arabinonucleosides/cerebrospinal fluid , Area Under Curve , Chromatography, High Pressure Liquid/methods , Clofarabine , Infusions, Intravenous , Macaca mulatta , Mass Spectrometry , Metabolic Clearance Rate
7.
Cancer Chemother Pharmacol ; 54(2): 127-30, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15150671

ABSTRACT

PURPOSE: The rebeccamycins, indolocarbazole topoisomerase I poisons originally discovered in actinomycetes, have shown activity in vitro against a range of adult and pediatric tumors. The derivative NSC 655649 (diethylaminoethyl analog of rebeccamycin, or DEAE rebeccamycin) is currently undergoing early-phase human studies and has shown some signs of antitumor activity. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of NSC 655649 after systemic administration in a nonhuman primate model that is predictive of anticancer drug behavior in humans. DESIGN: A dose of 400 mg/m2 was infused over 1 h to three rhesus monkeys. Serial blood and CSF samples were collected. Rebeccamycin concentrations were measured by high-pressure liquid chromatography. Pharmacokinetic analysis was performed using compartmental and noncompartmental methods. RESULTS: A two-compartment or three-compartment model described rebeccamycin pharmacokinetics in plasma adequately. In two animals, the three-compartment model provided a better fit, and in one animal, the two-compartment model was better. The terminal half-life was 730+/-410 min, the AUC was 3130+/-425 microM min, and the clearance was 190+/-25 ml/min/m2. Rebeccamycin was below the limit of quantitation in all CSF samples. The animals had some nausea and agitation during and shortly after the infusion that responded to treatment with prochlorperazine or diazepam. Otherwise, rebeccamycin was well tolerated with minimal toxicity. CONCLUSION: Rebeccamycin penetrates poorly into the CSF following an intravenous infusion. Therefore, systemically administered rebeccamycin is unlikely to be an important agent for the treatment of leptomeningeal tumors. Because the drug is associated with local irritation at injection sites, it is not an ideal candidate for development as an intrathecal agent. However, the role of rebeccamycin in the treatment of parenchymal brain tumors should be determined in clinical trials.


Subject(s)
Carbazoles/pharmacokinetics , Indoles/pharmacokinetics , Models, Theoretical , Animals , Area Under Curve , Blood-Brain Barrier , Carbazoles/administration & dosage , Cerebrospinal Fluid/chemistry , Indoles/administration & dosage , Infusions, Intravenous , Macaca mulatta , Male , Meningeal Neoplasms/drug therapy
8.
Lab Anim (NY) ; 31(10): 37-9, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12404014

ABSTRACT

Nonhuman primates might experience stress during periods of restraint associated with research procedures. In an attempt to minimize such stress, the authors describe an enrichment program they designed for use with restrained adult male rhesus macaques.


Subject(s)
Animal Husbandry/methods , Behavior, Animal , Immobilization/adverse effects , Macaca mulatta , Restraint, Physical/psychology , Social Environment , Animals , Male , Research Design , Stress, Physiological/prevention & control , Veterinary Medicine/methods
SELECTION OF CITATIONS
SEARCH DETAIL